5
Agilent Early Career Professor Award Winner
Dr. Jindan Yu, assistant professor of medicine at Northwestern University in Evanston, Ill. has been awarded the fifth annual Agilent Early Career Professor Award which endows $100,000 in unrestricted research funding
Dr Yu joined the faculty in the department of medicine at Northwestern University in 2009. Her research uses genomics and bioinformatics to better understand the progression of prostate cancer. Her aim is to develop novel prognostic/diagnostic tools and treatment strategies.
This year’s award focused on cancer diagnostics, a field of increasing importance to Agilent, which acquired Dako, a worldwide provider of cancer diagnostics last year.
To qualify for the award, a professor must make
significant contributions to the subset of cancer diagnostics aimed at multi-analyte tools for proteomic and/or genomic biomarkers in pathology. Yu has discovered several biomarkers associated with prostate cancer.
“It’s always a great honour to have the work of a faculty member recognised, especially early in her career,” said Jay Walsh, vice president for research at Northwestern University. “The Office for Research congratulates Dr. Yu and thanks Agilent Technologies for awarding her this recognition.”
“We recognise Dr. Yu for her original and important results in cancer genomics and bioinformatics, and we are looking forward to following her future research in cancer diagnostics,” said Jack Wenstrand, director of university relations and external research at
Agilent. “Our global call for nominations resulted in a remarkable pool of finalists, and we congratulate Dr. Yu, winner of this competitive award.”
Find out more circle no. 7 SKA Opens Headquarters in UK
to the Lovell Telescope at the University of Manchester’s Jodrell Bank Observatory in the UK..
UK Minister for Universities and Science the Rt. Hon. David Willetts MP unveiling the commemorative plaque for the SKA’s international headquarters opening ceremony. Credit: SKA
Less than a year after siting the revolutionary Square Kilometre Array (SKA) in Southern Africa and Australia, the SKA Organisation has opened its new international headquarters located near
"The Square Kilometre Array is set to be one of the world’s most exciting international science projects, giving us new and unparalleled insights into the universe”, said David Willetts MP, who conducted the opening ceremony of the new headquarters. “The fact that the UK has been chosen to host the project office is recognition of our leading expertise in science, engineering and design. It will give us a leading role in the development and operation of this groundbreaking telescope."
“The opening of the SKA headquarters at Jodrell Bank means that the world's largest radio telescope now has a home in the UK – a major milestone for this truly inspirational international
science project to explore the origin and evolution of the Universe”, said John Womersley, CEO of the Science and Technology Facilities Council (STFC) and Chairman of the SKA Organisation.
The £3.34 million building, funded by the University of Manchester, will eventually house upwards of 60 members of staff, including visiting scientists and engineers.
Built in the remote and radio quiet deserts of Australia and Southern
Africa, the array
comprises of thousands of radio telescopes and will also have dishes and antennas spread over thousands of kilometres to create a single giant telescope. Very faint radio waves are combined using powerful supercomputers making SKA more than 50 times more sensitive than any existing radio telescope on Earth.
Find out more circle no. 8 Industry Evidence sets Animal Welfare Benchmark
A multi-national industry collaboration has set new animal welfare guidelines since reviewing limits to determine the maximum-tolerated dose of a drug candidate used in short-term toxicity studies. The project, led by the UK’s National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) and AstraZeneca, used data from toxicity studies of up to seven days duration and concluded that a new upper limit of 10% bodyweight loss could be used as a primary endpoint for selecting the highest dose of a drug that could be tolerated in dogs and rats. The results of the study, which involved 15 pharmaceutical companies and contract research organisations have been published in Regulatory Toxicology and Pharmacology.
Along with the new recommended limits, an alert system has been developed to determine when the maximum-tolerated dose has been reached. While bodyweight loss is used here as an objective measurement, the presence of other clinical signs is also incorporated to add value to this practical advice. These standardised assessment criteria will minimise the adverse effects experienced by thousands of animals used in pharmaceutical development each year.
Maximum-tolerated dose studies are important from both a scientific and ethical perspective. They are used to make decisions on the progression of potential candidate drugs across a range of therapeutic areas. They also set the dose level for subsequent studies that allow for regulatory approval.
This approach to re-assessing bodyweight loss has the potential to be translated to other research areas including pharmacology and efficacy studies and short-term toxicity studies with chemicals.
Find out more circle no. 9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196 |
Page 197 |
Page 198 |
Page 199 |
Page 200 |
Page 201 |
Page 202 |
Page 203 |
Page 204 |
Page 205 |
Page 206 |
Page 207 |
Page 208 |
Page 209 |
Page 210 |
Page 211 |
Page 212 |
Page 213 |
Page 214 |
Page 215 |
Page 216 |
Page 217 |
Page 218 |
Page 219 |
Page 220 |
Page 221 |
Page 222
